HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Authors:
- 9 December 2021
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 23 (1) , 172-184
Abstract
No abstract availableKeywords
Funding Information
- Harvard Medical School
- U.S. Department of War (KC170216, KC190128T, KC190130)
- Dana-Farber Cancer Institute
- U.S. Department of Health and Human Services
- Pfizer Ltd
- National Cancer Institute
- Merck KGaA
- Pfizer
- Frederick National Laboratory for Cancer Research (HHSN261200800001E)
- Merck
- National Institutes of Health
This publication has 29 references indexed in Scilit:
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaClinical Cancer Research, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- A global reference for human genetic variationNature, 2015
- Epigenetic regulation of differentialHLA-Aallelic expression levelsHuman Molecular Genetics, 2015
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2015
- Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registryHuman Immunology, 2013
- Imputing Amino Acid Polymorphisms in Human Leukocyte AntigensPLOS ONE, 2013
- Protective HIV-specific CD8+ T cells evade Treg cell suppressionNature Medicine, 2011
- Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in TaiwanNew England Journal of Medicine, 2011
- Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In VivoThe Journal of Immunology, 2006